Assessing the Incidence Rate of Neuropsychiatric Adverse Effects in Older Adults Following Levetiracetam Initiation: A Retrospective Study
DOI: https://doi.org/10.2147/ijgm.s458803
IF: 2.145
2024-05-08
International Journal of General Medicine
Abstract:Mazen A Basheikh 1, 2 1 Department of Internal Medicine, Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia; 2 Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia Correspondence: Mazen A Basheikh, Department of Medicine, Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia, Tel +966504325067, Email Background: Levetiracetam (LEV) is commonly prescribed for epilepsy management. However, neuropsychiatric disorders (NPDs) are concerning adverse effects that may result in medication discontinuation. This study aims to examine the incidence and factors influencing LEV associated NPDs in adult patients aged 50 years and above. Methods: A retrospective analysis was conducted on patients aged 50 years and above prescribed LEV between 2010 and 2020, with at least one follow-up appointment six months post-treatment initiation. The incidence of new-onset or aggravated NPDs and variables potentially influencing this risk were examined. Independent t -test, chi-squared, and Fisher's exact test were used, in addition to univariate and multivariate logistic regression. Results: The study included 100 patients with a mean age at LEV start of 63.31 years (SD = 16.48). Neuropsychiatric symptoms were observed in 6 (6.0%) patients. Factors associated with new-onset NPDs were younger age at epilepsy diagnosis (p=0.005), younger age at LEV start (p=0.004), and concurrent use of Carbamazepine/Oxcarbazepine (p=0.004). On multivariate analysis, only the association with Carbamazepine/Oxcarbazepine remained significant (OR 14.62, 95% CI 1.86– 114.70, p=0.011). Conclusion: The findings indicate that the incidence of NPDs in elderly patients is relatively low (6%). Further research with larger samples is needed in comparison with a younger sample as a control group to confirm these findings. Keywords: levetiracetam, neuropsychiatric disorders, elderly patients Epilepsy is a common neurological disorder characterized by a sustained propensity to generate epileptic seizures, leading to a spectrum of cognitive, psychological, and social repercussions. It manifests with transient motor (the most frequent), sensory, sensitive, autonomic, or cognitive symptoms originating from abnormal excessive or synchronous neuronal activity within the brain that results from an imbalance between excitation and inhibition of neuronal circuits. 1 According to the WHO, it is estimated that 5 million people are diagnosed with epilepsy every year worldwide, with about 80% of epileptic patients living in low- and middle-income countries. 2 Nonetheless, the availability of effective antiseizure agents considerably reduced the burden of this disorder, as over 70% of the affected individuals can live seizure-free if properly diagnosed and treated. 2 Levetiracetam (LEV), a pyrrolidone derivative developed from piracetam, is among the first-line medications for epilepsy. It has demonstrated tolerability and effectiveness against both focal and generalized seizures in children and adults. 3,4 The pharmacological effects of LEV are attributed to its modulation of neuronal activity through various mechanisms. It binds to the synaptic vesicle protein 2A (SV2A), a glycoprotein essential for presynaptic neurotransmission present mainly in the cortex, thalamus, basal ganglia, and hippocampus, leading to a decreased seizure threshold in epileptogenic brain areas. 5 Furthermore, LEV has additional potential antiseizure effects. It increases the levels of the inhibitory neurotransmitter GABA and neurosteroids such as allopregnanolone, while decreasing excitatory glutamate. It also modulates serotonergic, α2-adrenergic, and μ-opioid receptor-mediated signaling, and reduces intraneuronal calcium levels. 6,7 However, these effects of LEV can result in secondary interference with other neurological functions such as mood and behavior regulation, ultimately leading to neuropsychiatric disorders (NPDs). 6 A case–control study involving 841 patients with a mean age of 44.7 years old showed that LEV therapy was independently associated with greater frequency of anger/aggression, nervousness/agitation, depression, and sleep disturbance, compared to other treatments. 8 In another large case–control study of 4085 epilepsy patients (mean age: 41 years), LEV displayed the highest rates of psychiatric adverse events compared to the other antiseizure medications (ASMs). These effects resulted in higher intolerability rate of 17.7%, a dose reduction rate of 9.8% and complete cessation rate of 8.3%. 3 Moreover, previous systematic reviews of safety revealed that following LEV therapy, the inciden -Abstract Truncated-
medicine, general & internal